COMMUNIQUÉS West-GlobeNewswire

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026
06/05/2026
LONDON and PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology [...]
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
06/05/2026
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated [...]
IBA Introduces myQA StarTrack³ for Fast, High Resolution Linac QA with a Single Detector Setup
06/05/2026
One setup. One detector. Complete beam insight. Louvain-la-Neuve, Belgium, 06 May 2026 – (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global provider of dosimetry and [...]
IBA lance myQA StarTrack³ une solution haute résolution pour une assurance qualité des accélérateurs linéaires rapide et précise, avec une seule mise en place du détecteur
06/05/2026
Une installation. Un détecteur. Une caractérisation complète du faisceau. Louvain-la-Neuve, Belgique, 6 mai 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial de la technologie d'accélérateurs de [...]
Philips delivers strong order intake, comparable sales growth and margin expansion in Q1; 2026 outlook reiterated
06/05/2026
May 6, 2026 Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA [...]
Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026
06/05/2026
Bagsværd, Denmark, 6 May 2026 - Financial report for the period 1 January 2026 to 31 March 2026 Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related [...]
WriteUpp Introduces Embedded AI Medical Scribe With SOAP, DAP and BIRP Note Generation at CA$40 Per User
06/05/2026
The new per-user add-on brings structured AI clinical documentation into Notes, Documents, and Assessments, giving Canadian therapists, physiotherapists, and allied health professionals a flexible and compliant way to [...]
LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis
06/05/2026
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has [...]
Rapid Nutrition Enhances Investor Access with Agentic AI driven On-Demand Communication Platform
06/05/2026
LONDON, May 05, 2026 (GLOBE NEWSWIRE) -- Rapid Nutrition PLC (Euronext Growth: ALRPD ), a global HealthTech company advancing wellness through evidence-based, personalized nutrition solutions, today announced the [...]
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
05/05/2026
Successfully met primary endpoint of HiSCR75 for both doses studied, demonstrating response rates of 42.2% for 150 mg dose (p=0.018) and 42.9% for 300 mg dose (p=0.015) at Week 16, which are the highest rates observed [...]
STERIS Announces Dividend of $0.63 per share
05/05/2026
DUBLIN, IRELAND, May 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Korro to Participate in Upcoming Investor Conferences
05/05/2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class [...]
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/05/2026
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today [...]
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
05/05/2026
First quarter total revenue of $136 million, Crysvita® revenue of $93 million and Dojolvi® revenue of $18 million Reaffirm 2026 financial guidance, including total revenue of $730 million to $760 million and combined R [...]
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
05/05/2026
Highl ights First quarter 2026 revenue of $200.4 million grew 2% year-over-year, reflecting stable test volume and 2% year-over-year growth in average revenue per test. First quarter 2026 test volume reflects 13% and 7 [...]
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
05/05/2026
U.S. Launch of MYQORZO ® (aficamten) in Late January Met with Strong Demand; Over 275 HCPs Prescribed MYQORZO to an estimated 680 Patients in Q1 ACACIA-HCM Met Dual Primary Endpoints of KCCQ and Maximal Exercise [...]
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
05/05/2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2026
05/05/2026
DENVER, May 05, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Dentsply Sirona Reports First Quarter 2026 Results
05/05/2026
News Summary Reported net sales of $880 million Delivered GAAP gross margin of 48.5% , GAAP net loss per share of ($0.05) Achieved adjusted gross margin of 50.7% , adjusted EBITDA margin of 14.7% , adjusted EPS of $0.27 [...]

Pages